Literature DB >> 30255734

Direct-to-consumer marketing of stem cell interventions by Canadian businesses.

Leigh Turner1.   

Abstract

AIM: This study examines marketing claims of Canadian businesses engaged in direct-to-consumer advertising of putative stem cell treatments.
METHODS: Internet searches were used to locate Canadian businesses selling stem cell interventions. Company websites were subjected to detailed analysis.
RESULTS: In total, 30 Canadian businesses sell stem cell interventions provided at 43 clinics. Autologous stem cells are the most common types of products promoted by such businesses. Company websites minimize risks while making strong claims about benefits of stem cell interventions. DISCUSSION: Businesses' representations could result in patients making health-related decisions informed by marketing claims rather than best available scientific evidence.
CONCLUSION: Although there is absent development of new regulations and guidance, the Canadian direct-to-consumer marketplace for stem cell interventions appears poised for expansion.

Entities:  

Keywords:  Canada; Health Canada; clinics; direct-to-consumer marketing; empirical analysis; physicians; stem cells

Mesh:

Year:  2018        PMID: 30255734     DOI: 10.2217/rme-2018-0033

Source DB:  PubMed          Journal:  Regen Med        ISSN: 1746-0751            Impact factor:   3.806


  8 in total

Review 1.  Ethical development of stem-cell-based interventions.

Authors:  Amanda MacPherson; Jonathan Kimmelman
Journal:  Nat Med       Date:  2019-07-03       Impact factor: 53.440

2.  On Patient Safety: Regenerative Medicine-The Hype Amplifies Safety Concerns.

Authors:  James Rickert
Journal:  Clin Orthop Relat Res       Date:  2019-07       Impact factor: 4.176

3.  Financial risks posed by unproven cell interventions: Estimation of refunds from medical expense deductions in Japan.

Authors:  Taichi Hatta; Kazuki Ide; Misao Fujita; Tsunakuni Ikka
Journal:  Stem Cell Reports       Date:  2022-04-21       Impact factor: 7.294

Review 4.  Looking into the future: Gene and cell therapies for glaucoma.

Authors:  András M Komáromy; Kristin L Koehl; Shin Ae Park
Journal:  Vet Ophthalmol       Date:  2021-01-07       Impact factor: 1.644

5.  The law and problematic marketing by private umbilical cord blood banks.

Authors:  Blake Murdoch; Alessandro R Marcon; Timothy Caulfield
Journal:  BMC Med Ethics       Date:  2020-07-01       Impact factor: 2.652

6.  Closing gaps, opening doors: an experimental collaboration in stem cell intervention.

Authors:  Fabio Rossi; Martin Braun; Jonathan Brock; Janette Sen-Lum; Sonya Ellens; Elliot Lander; Douglas Stoddard; Carolyn Cross; Angelika Vance; Duncan Stewart; Bernard Thebaud; Judy Illes
Journal:  Mol Biol Rep       Date:  2020-05-06       Impact factor: 2.316

7.  Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action.

Authors:  Timothy Caulfield; Blake Murdoch
Journal:  BMC Med Ethics       Date:  2019-08-06       Impact factor: 2.652

8.  Regulated, reliable, and reputable: Protect patients with uniform standards for stem cell treatments.

Authors:  Geoffrey P Lomax; Art Torres; Maria T Millan
Journal:  Stem Cells Transl Med       Date:  2020-02-10       Impact factor: 6.940

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.